Capital to Fund Expanded Commercial Operations and Broaden Product Portfolio
SAN DIEGO, June 2, 2014 (GLOBE NEWSWIRE) — Sente Inc., a privately held specialty aesthetics company pioneering the development of differentiated skincare products based on the science of glycoproteins, announced today the close of a $5 million Series C financing. The newly raised capital will fund expanded sales and marketing operations to broaden the portfolio of Sente physician dispensed skincare products.
The Series C financing, which included both existing and new individual investors, was led by PharmaBio Investments Inc., a Durham, NC based investment firm.
“We are very pleased to see a continued strong interest in our company from leading life science investors,” commented Michael York, President and Chief Executive Officer of Sente, Inc. “We remain committed to bringing to market differentiated medical grade skin care products based on our patented low molecular weight heparan sulfate (HS) technology by expanding our portfolio to include three new products by the end of 2014.”
“Sente was established to focus on the science of dermatology and to create proprietary medical grade specialty aesthetic products,” added Kleanthis G. Xanthopoulos, Ph.D., Co-Founder and member of the Board of Sente, Inc. “We are very happy to have assembled such an outstanding group of investors to help support our mission.
About Sente, Inc.
Sente, Inc., a privately held specialty aesthetics company, is a recognized leader in the development of innovative and targeted skincare products utilizing HSA technology, a low molecular weight formulation of heparan sulfate. HSA is essential for skin hydration, rejuvenation and necessary for healthy-looking skin. Sente was founded in 2007 and is based in San Diego, California. Further information may be found at https://sentelabs.com/. Sente products are available through an exclusive network of physicians, medically supervised spas.
SENTÉ Press Contact:
Creative Media Marketing
sente@cmmpr.com
(212) 979-8884